+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the use of PET imaging with the radioligand 18FPI-2620 to detect tau protein buildup in people with Alzheimers disease and control subjects. This open-label, multi-center, pivotal Phase 3 study compares imaging results during life to brain tissue analysis after death to assess the accuracy and safety of this diagnostic method. Participants will receive an intravenous injection of 18FPI-2620 at a dose of 185 MBq 20%. This study is non-randomized and single-group, focusing on the imaging procedure itself without placebo or alternative treatments. The study will continue until autopsy and brain tissue analysis are completed, with an average follow-up period of about one year. During the study, participants will undergo PET scans using 18FPI-2620. Researchers will assess the scans ability to correctly identify tau pathology related to Alzheimers disease by comparing them to post-mortem brain tissue analysis. The study includes safety monitoring and evaluation of the agreement between different readers interpreting the scans. Overall participation lasts until the participants death and brain autopsy, expected on average around one year after the scan.

Age: 50Years +All GendersPhase 3
25 locations
E

Actively Recruiting

Researchers are evaluating whether donanemab, given as an intravenous infusion, can slow down the worsening of thinking, learning, memory, attention, and daily functioning in people with early cognitive decline and features of dementia with Lewy bodies. This phase 2 study focuses on participants aged 55 to 85 who show evidence of both amyloid and alpha-synuclein brain pathology. The trial is randomized and placebo-controlled to compare donanemab against a placebo. Participants will receive either donanemab or a placebo via IV infusion during the study. The treatment period lasts up to 52 weeks, during which various clinical and biomarker assessments will be conducted. The study includes monitoring for drug concentrations and immune responses. Both groups receive infusions under a quadruple-masked design to ensure unbiased results. Throughout the one and a half year participation, participants will be regularly evaluated using cognitive and functional tests like the Clinical Dementia Rating scale, Alzheimers Disease Rating Scales, and brain imaging to measure amyloid plaque levels. Safety assessments include monitoring for adverse effects and antibody development. Study partners familiar with the participants daily abilities provide additional information. The study aims to observe changes from baseline over the 52-week treatment period.

Age: 55Years - 85YearsAll GendersPhase 2
72 locations
E

Actively Recruiting

Researchers are evaluating how well JNJ-101556143 works in people with metastatic androgen pathway modulation-resistant prostate cancer mAPMR, a form of advanced prostate cancer that no longer responds to hormone therapy. This study aims to measure the overall response, including tumor shrinkage or disappearance, after treatment with this investigational drug. The trial is a Phase 2, open-label, multicenter, single-arm study sponsored by Janssen Research & Development, LLC. Participants will receive JNJ-101556143 orally once daily in 28-day treatment cycles. Treatment continues until the disease shows confirmed progression by imaging or clear clinical signs, or if other protocol-defined reasons require stopping. The study evaluates the drugs effects over up to 2 years and 8 months, including response duration, progression-free survival, and time to symptom progression. During the trial, participants will undergo regular assessments including imaging scans, laboratory tests, and measurements of drug levels in the blood to monitor response and safety. Researchers will track adverse events and clinical lab abnormalities throughout. The primary outcome is the overall response rate measured over nearly three years. Participants remain on study until progression or discontinuation criteria are met, with ongoing safety and disease monitoring throughout their participation.

Age: 18Years +MALEPhase 2
14 locations
R

Actively Recruiting

Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.

Age: 18Years +MALEPhase 3
346 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.

Age: 18Years +All GendersPhase 3
115 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of TYRA-300 in adults with FGFR3 altered low grade, intermediate risk non-muscle invasive bladder cancer NMIBC. This phase 2, multicenter, open-label study focuses on patients who have specific genetic alterations in the FGFR3 gene and have a confirmed low-grade NMIBC tumor. The purpose is to better understand how this oral drug works in this specific group of bladder cancer patients. Participants will receive one of three self-administered daily doses of the study drug TYRA-300 as oral tablets 50 mg, 60 mg, or 70 mg. The study is randomized and parallel in design, with all participants receiving the active drug in different dose cohorts. The drug is taken daily and treatment effects will be assessed over time, with follow-up lasting up to 24 months in some cases. During the study, participants will undergo regular assessments to monitor the drugs effects and safety, including evaluations of tumor response and recurrence. Key measures include the rate of complete response at 3 months, overall response rates up to 24 months, and the duration of response. Safety will be monitored through adverse event tracking. Participants will be followed for up to two years to assess longer-term outcomes and any side effects associated with TYRA-300.

Age: 18Years +All GendersPhase 2
48 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
E

Actively Recruiting

Researchers are evaluating Dabogratinib TYRA-300 in a Phase 2AB study involving participants with Low Grade Upper Tract Urothelial Carcinoma LG UTUC. This open-label, multi-center trial aims to assess the safety and effectiveness of Dabogratinib in treating this specific type of urothelial carcinoma, focusing on participants with FGFR3 positive tumors. The study is sponsored by Tyra Biosciences, Inc and includes randomized treatment groups receiving different doses of Dabogratinib. Participants receive Dabogratinib as a self-administered oral tablet daily at either 60mg or 80mg doses. The study includes two treatment cohorts and is designed to monitor the drugs impact on tumor response, including complete response rates and duration of response. The trial allows evaluation over a period of up to 36 months for response duration and up to 2 years for safety, renal preservation, and tumor resectability changes. During the trial, participants undergo assessments to measure tumor response, safety, and tolerability. Marker lesions are identified prior to randomization and monitored throughout. Researchers track outcomes including complete response rates within 6 months, maintenance of response at 12 and 24 months, and kidney function preservation. Laboratory tests, imaging, and clinical evaluations are performed regularly. The total participation time can extend up to several years to capture long-term effects and safety data.

Age: 18Years +All GendersPhase 2
36 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TARA-002, a biological preparation containing cells of Streptococcus pyogenes, in adults 18 years and older with high-grade non-muscle invasive bladder cancer NMIBC including carcinoma in situ CIS with or without TaT1. This Phase 2 open-label study aims to further assess TARA-002 at the recommended Phase 2 dose established in a prior dose-finding study. Participants include those who are BCG naive, BCG exposed but not recently treated, or BCG unresponsive. Participants will receive intravesical instillations of TARA-002 in a structured treatment schedule. The first period consists of 6 weekly doses. Those eligible for reinduction will receive another 6 weekly doses, while participants with a complete response after the first period will get 3 weekly maintenance doses. A third treatment period includes 3 weekly maintenance doses administered at months 6, 9, 12, 15, 18, and 24. Following treatment, participants enter a follow-up period lasting from month 27 to month 60. Throughout the study, participants will be monitored for tumor response, including high-grade complete response rates and duration, progression-free survival, cystectomy timing, and survival outcomes up to 60 months. Safety assessments include monitoring adverse events and biomarker changes in urine. Quality of life questionnaires will be administered up to 24 months. This comprehensive evaluation aims to understand TARA-002s effects and safety over time in this patient population.

Age: 18Years +All GendersPhase 2
78 locations
R

Actively Recruiting

Researchers are evaluating the drug LHP588 in individuals aged 55 to 80 years who have mild to moderate Alzheimers disease AD and a confirmed infection with the bacterium P. gingivalis Pg. The study explores whether targeting this bacterium can slow or stop the progression of AD symptoms. Participants must have shown progressive cognitive decline in the past year, and the diagnosis is confirmed using standard criteria and tests including MMSE and plasma pTau217 levels. The study is a randomized, double-blind, placebo-controlled trial where participants are assigned to one of three groups receiving either 25 mg or 50 mg of LHP588 or placebo once daily for 48 weeks. The treatment period includes a 2-week dose escalation for the higher dose group. Before treatment, participants undergo a screening period lasting up to 12 weeks to confirm eligibility, including saliva tests for Pg infection and brain MRI to rule out other causes of dementia. After treatment, a 4-week safety follow-up monitors participants health. During the study, participants and their caregivers will visit the study center at least 20 times over about 64 weeks. Assessments include cognitive and functional tests like ADAS-Cog, ADCS-ADL, CMAI, and CDR-SB, as well as physical exams, blood tests for pharmacokinetics and biomarkers, saliva tests for Pg infection, ECGs, and safety labs. A phone call will also be made during the safety follow-up. The main outcome measured is change in cognitive function using ADAS-Cog11 between weeks 40 and 48.

Age: 55Years - 80YearsAll GendersPhase 2
39 locations

1-10 of 11

1